ClearPoint Neuro (CLPT) risk factors
Item 1A of every ClearPoint Neuro, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors69 risks18 new6 dropped15 reworded
The acquisition of IRRAS dominates this year's risk additions, bringing new manufacturing, clinical, and commercial integration challenges. The company faces heightened execution risks expanding its ClearPoint and IRRAflow systems into operating rooms and neurocritical care units. Single-source supply chain dependencies and regional facility disaster risks remain prominent.
Filed Mar 17, 2026 - FY2024 10-K risk factors57 risks
ClearPoint Neuro faces high customer concentration, with one pharmaceutical partner accounting for 9 percent of total revenues and 17 percent of clinical service revenues in 2024. Operations depend on a single manufacturing facility in Carlsbad, California, exposing the company to fire and earthquake risks. The cumulative net loss reached 191.4 million dollars by the end of 2024.
Filed Feb 26, 2025